|
Jul 2
|
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
|
|
Jun 30
|
I-Mab Announces Publication of Givastomig Monotherapy Data in Clinical Cancer Research
|
|
Jun 26
|
June 2025's Promising Penny Stocks
|
|
Jun 26
|
I-Mab Highlights Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
|
|
Jun 18
|
I-Mab to Host Webinar to Recap New Givastomig Data, in Combination with Immunochemotherapy, Expected at ESMO GI 2025
|
|
Jun 6
|
I-Mab Sponsored ADR (IMAB) is a Great Momentum Stock: Should You Buy?
|
|
May 23
|
Fuel Tech And 2 Other Promising Penny Stocks For Consideration
|
|
Apr 14
|
After Plunging -20.33% in 4 Weeks, Here's Why the Trend Might Reverse for IMab (IMAB)
|
|
Oct 9
|
IMab (IMAB) Moves to Buy: Rationale Behind the Upgrade
|
|
Jul 15
|
I-Mab Announces Leadership Transitions
|
|
May 2
|
Q1 2024 Summit Therapeutics Inc Earnings Call
|
|
Apr 30
|
I-MAB Filed 2023 Annual Report on Form 20-F
|
|
Apr 5
|
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
|
|
Apr 2
|
I-Mab Announces Closing of the Divestiture of Business Operations in China
|
|
Mar 18
|
I-Mab Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Mar 14
|
I-Mab Reports Full Year 2023 Financial Results and Business Update
|
|
Feb 7
|
UPDATE 2-Biotech firm I-Mab to divest China operations, shift focus to US
|
|
Feb 7
|
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
|
|
Nov 6
|
I-Mab Announces Participation at Jefferies and Piper Conferences in November
|
|
Nov 2
|
Felzartamab Granted Breakthrough Therapy Designation by U.S. Food and Drug Administration (FDA) for Primary Membranous Nephropathy (PMN)
|